• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Miravant gets FDA list for SnET2 marketing nod

Article

Santa Barbara, CA-Miravant Medical Technologies will launch an additional clinical trial in an effort to meet the FDA's conditions for final marketing approval of its tin ethyl etiopurpurin (SnET2).

Santa Barbara, CA-Miravant Medical Technologies will launch an additional clinical trial in an effort to meet the FDA's conditions for final marketing approval of its tin ethyl etiopurpurin (SnET2).

The FDA called for an additional confirmatory clinical trial, among other conditions, when it issued its approvable letter recently for SnET2, a light-activated drug designed to stabilize vision loss by selectively destroying the leaking vessels associated with wet age-related macular degeneration (AMD).

Phase III clinical trials of the drug showed improvement in a range of choroidal neovascularization lesions, regardless of the percent classic component or presence of occult component.

"We expect that this guidance, coupled with the knowledge we have gained about wet AMD through the phase III studies, should enable us to fulfill the requirements efficiently," he said.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.